Nexstim

Nexstim is located in Helsinki, Finland on Elimäenkatu 9 B. Nexstim is rated 3 out of 5 in the category medical devices in Finland. Nexstim is the world leader in image-guided transcranial magnetic stimulation (TMS) Founded in 2000 in Helsinki, Finland, Nexstim is committed to improving the quality of life of patients with significant unmet clinical needs. We have developed a world-leading SmartFocus TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). Our system, with the highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD. Nexstim’s NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain. In addition, we have a pioneered the technology for brain diagnostics and we hold the only FDA-clearances for non-invasive pre-surgical mapping with the Navigated Brain Stimulation (NBS) System for the primary motor cortex and NexSpeech® for speech and language function. NBS is recognized as the emerging standard for pre-operative direct functional mapping. Our NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.